0000950170-24-041438.txt : 20240403
0000950170-24-041438.hdr.sgml : 20240403
20240403194021
ACCESSION NUMBER: 0000950170-24-041438
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240401
FILED AS OF DATE: 20240403
DATE AS OF CHANGE: 20240403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bellon Christine
CENTRAL INDEX KEY: 0001963878
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39208
FILM NUMBER: 24820980
MAIL ADDRESS:
STREET 1: BEAM THERAPEUTICS, INC.
STREET 2: 238 MAIN STREET, 9TH FL.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Beam Therapeutics Inc.
CENTRAL INDEX KEY: 0001745999
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-327-8775
MAIL ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
ownership.xml
4
X0508
4
2024-04-01
0001745999
Beam Therapeutics Inc.
BEAM
0001963878
Bellon Christine
C/O BEAM THERAPEUTICS INC.,
238 MAIN STREET
CAMBRIDGE
MA
02142
false
true
false
false
Chief Legal Officer
true
Common Stock
2024-04-01
4
S
false
3401
32.12
D
104594
D
These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.09 to $32.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
By: /s/ Christine Bellon
2024-04-03